The firms will jointly study the combination, and Sanofi will have an exclusivity period to negotiate the in-licensing of KN026, contingent on certain milestones.
The studies highlighted the activity of three drugs in NSCLC patients characterized by HER2 mutations, CECAM5 overexpression, and high PD-L1 expression.
The data from the trial will support regulatory submissions in the US and EU for Libtayo as a first-line option for PD-L1 positive non-small cell lung cancer patients.
